Back to results
US 2026/0158042 A1Published application
Method and Composition for an Improved Bioavailability Delivery System
AssigneeAmericana Pharma LLC
InventorAman Beri
Life of this patent
Estimating the term…
Abstract
A method of forming a DHEA derivative supplement including adaptogens, modified stilbenoids complex, non-esterified omega-3 fatty acids, essential amino acids, HMB free acid, vitamins, L-arginine, creatine, green tea extracts, and chelated minerals, in a multi-bioavailability delivery system, based on the nature of the constituents, formed as an encapsulated micronized material having a phytosomal delivery system which reduces supplements dosage while increasing active nutrients efficacy and bioavailability by providing a targeted delivery system for nutritional effects.
Claims20
A method of forming a targeted release dietary supplement delivery system comprising the steps of:
- micronizing a predetermined quantity of bioactive agents selected from the group consisting of DHEA derivatives, HMB free acid, and free fatty acids until the compound is in a dry, free-flowing powder form of less than ten microns and performing a quality control of the DHEA derivative and determining that no chemical degradation has occurred, wherein the DHEA derivative is un-esterified and free of any ester or acyl substitution at its hydroxyl positions, and encompasses both saturated and unsaturated androstane and androstene analogs, including dione, diol, triol, hydroxy-keto, and dehydrogenated variants having optional double bonds at positions 1, 4, or 5 of the carbon backbone;
- pre-processing the DHEA derivatives, HMB free acid, and free fatty acids independently, prior to blending with other components;
- micronizing a predetermined quantity of cyclodextrin and performing a quality control of the micronized cyclodextrin;
- micronizing a predetermined quantity of Siberian ginseng extract;
- micronizing a predetermined quantity of omega-3 fatty acids;
- micronizing a predetermined quantity of vitamin B6;
- micronizing a predetermined quantity of trans-resveratrol;
- forming a phytosome complex from poorly soluble herbals selected from the group consisting of ashwagandha and ginseng, the group being pre-formed prior to blending with other formulation components;
- blending the pre-processed group consisting of DHEA derivatives, HMB free acid, and free fatty acids after micronization with the cyclodextrin until both have the same particle size;
- adding the phytosome complex to the pre-processed DHEA derivatives, with the cyclodextrin, Siberian ginseng extract, omega-3 fatty acids, vitamin B6, trans-resveratrol, and HMB free acids;
- and
- encapsulating the resulting mixture.
9 more elements
A targeted release dietary supplement delivery system comprising:
- a predetermined quantity of micronized bioactive agents selected from the group consisting of DHEA derivatives, HMB free acid, and free fatty acids in a dry, free-flowing powder form of less than ten microns, wherein a quality control of the DHEA derivative has determined that no chemical degradation has occurred, and wherein the DHEA derivative is un-esterified and free of any ester or acyl substitution at its hydroxyl positions, and encompasses both saturated and unsaturated androstane and androstene analogs, including dione, diol, triol, hydroxy-keto, and dehydrogenated variants having optional double bonds at positions 1, 4, or 5 of the carbon backbone;
- wherein the DHEA derivatives are pre-processed independently of the HMB free acid and free fatty acids prior to blending with other components;
- a predetermined quantity of micronized cyclodextrin;
- a predetermined quantity of micronized Siberian ginseng extract;
- a predetermined quantity of micronized omega-3 fatty acids;
- a predetermined quantity of micronized vitamin B6;
- a predetermined quantity of micronized trans-resveratrol;
- a phytosome complex formed from poorly soluble herbals selected from the group consisting of ashwagandha and ginseng, the group being pre-formed prior to blending with other formulation components;
- wherein the pre-processed group consisting of DHEA derivatives, HMB free acid, and free fatty acids are blended after micronization with the cyclodextrin until both have the same particle size;
- wherein the phytosome complex is added to the pre-processed DHEA derivatives, with the cyclodextrin, Siberian ginseng extract, omega-3 fatty acids, vitamin B6, trans-resveratrol, and HMB free acids;
- and
- wherein the resulting mixture is encapsulated.
9 more elements
Dependencies are inferred from the claim text.